BC Platforms Partners with CO-CONNECT Consortium to accelerate COVID-19 research

Debiopharm’s investment portfolio company BC Platforms was selected as data partner for the UK CO-CONNECT consortium working on Covid-19. BC Platform’s technology will be used to connect multiple data sources, including large cohort studies, to provide an accessible harmonized serology dataset that will give insights into patient immunity and treatment outcomes. The CO-CONNECT COVID consortium is led by Universities of Nottingham, Dundee, Edinburgh, and Public Health England.


Access the full press release here.